Alzheimer's disease drug development pipeline: 2017 Jeffrey Cummings, Garam Lee, Travis Mortsdorf, Aaron Ritter, Kate Zhong  Alzheimer's & Dementia: Translational Research & Clinical Interventions  Volume 3, Issue 3, Pages 367-384 (September 2017) DOI: 10.1016/j.trci.2017.05.002 Copyright © 2017 The Authors Terms and Conditions

Fig. 1 Agents in clinical trials for the treatment of Alzheimer's disease in 2017 (from clinicaltrials.gov accessed 1/5/2017). Abbreviations: ATP, adenosine triphosphate; BNC, bisnorcymserine; GM-CSF, granulocyte-macrophage colony-stimulating factor; OAA, oxaloacetate; IVIG, intravenous immunoglobulin; SLAT, simvastatin + L-arginine + tetrahydrobiopterin. Alzheimer's & Dementia: Translational Research & Clinical Interventions 2017 3, 367-384DOI: (10.1016/j.trci.2017.05.002) Copyright © 2017 The Authors Terms and Conditions

Fig. 2 Mechanisms of action of agents in phase II. Abbreviation: BACE, β-site amyloid precursor protein cleaving enzyme. Alzheimer's & Dementia: Translational Research & Clinical Interventions 2017 3, 367-384DOI: (10.1016/j.trci.2017.05.002) Copyright © 2017 The Authors Terms and Conditions

Fig. 3 Mechanisms of action of agents in phase III. Abbreviation: BACE, β-site amyloid precursor protein cleaving enzyme. Alzheimer's & Dementia: Translational Research & Clinical Interventions 2017 3, 367-384DOI: (10.1016/j.trci.2017.05.002) Copyright © 2017 The Authors Terms and Conditions

Fig. 4 Illustration of drug mechanism (phase III agents) and the proposed biology of Alzheimer's disease. (A) Amyloid cascade. (B) Downstream pathophysiology. Abbreviation: BACE, β-site amyloid precursor protein cleaving enzyme. Alzheimer's & Dementia: Translational Research & Clinical Interventions 2017 3, 367-384DOI: (10.1016/j.trci.2017.05.002) Copyright © 2017 The Authors Terms and Conditions